Indaptus Therapeutics (NASDAQ:INDP) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Indaptus Therapeutics (NASDAQ:INDP) to a sell rating in a research report sent to investors on Saturday.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Indaptus Therapeutics in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $140.00.

Indaptus Therapeutics Trading Down 2.2%

NASDAQ:INDP opened at $3.55 on Friday. The company has a market capitalization of $3.94 million, a P/E ratio of -0.09 and a beta of 1.13. Indaptus Therapeutics has a 12 month low of $2.22 and a 12 month high of $47.60. The business’s 50-day moving average is $4.13 and its 200 day moving average is $8.46.

Indaptus Therapeutics (NASDAQ:INDP) last posted its earnings results on Wednesday, August 13th. The company reported ($9.09) EPS for the quarter, missing analysts’ consensus estimates of ($0.36) by ($8.73). On average, research analysts forecast that Indaptus Therapeutics will post -1.79 earnings per share for the current year.

About Indaptus Therapeutics

Indaptus Therapeutics, Inc, a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial.